aap Implantate AG, DE0005066609

aap Implantate AG, DE0005066609

19.07.2017 - 10:26:17

aap Implantate AG: Resolution on a Capital Reduction

The Management Board of aap Implantate AG resolved on 19 July 2017 with the approval of the Supervisory Board of the same day to redeem the 2,249,746 no-par value shares bought by means of the voluntary public share buyback offer of aap Implantate AG and to reduce the company's share capital by the corresponding amount of EUR 2,249,746.00. The redemption and capital reduction take place without a further resolution of the Annual General Meeting by exercising the authorization of the Annual General Meeting of 13 June 2014. After the implementation of the capital reduction aap Implantate AG's share capital amounts to EUR 28,582,410.00 and is divided into 28,582,410 no-par value ordinary bearer shares in a proportional amount of EUR 1.00 per no-par value share of the share capital.

_______________________________________________________________________________________aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -About aap Implantate AGaap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.Forward-looking statement This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. Contact: For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

19-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: aap Implantate AG Lorenzweg 5 12099 Berlin

Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of Announcement DGAP News Service

593833  19-Jul-2017 CET/CEST

@ dgap.de